Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

FDA will use an August 6 webinar to explain its proposed Expedited IND Pilot Program, which aims to shorten the path from drug identification to first-in-human trials. The agency wants sponsors to work with qualified research institutions and use rolling
Eli Lilly’s retatrutide biologic dispute with the FDA has reached a critical point before a planned first-quarter 2027 filing. Lilly intends to pursue a Biologics License Application (BLA), while FDA has classified retatrutide as a drug requiring a New Drug
Novo Nordisk CEO Mike Doustdar said during the company’s August 5 earnings call that innovation will determine whether the Danish drugmaker can sustain long-term growth. His comments followed the Phase 3 ZEUS trial failure for ziltivekimab and other pipeline setbacks.
Pfizer reported stronger-than-expected second-quarter results on August 4 in New York and added $2.5 billion to its cost-reduction plan. The company now expects $9.7 billion in net savings through 2029 while raising the midpoint of its 2026 revenue outlook. This
Amgen announced on August 4 in Thousand Oaks, California, that it will end future development of AMG-513, its early-stage obesity candidate. However, the company will keep the Phase 1 trial running until enrolled participants complete follow-up. The decision matters because
Merck raised its 2026 revenue forecast after reporting stronger second-quarter sales on August 4 at its headquarters in Rahway, New Jersey. However, the company sharply reduced its adjusted earnings guidance because of charges linked to its acquisitions of Terns Pharmaceuticals
Sarepta Therapeutics appointed former Tessera Therapeutics chief Michael Severino as CEO, effective July 28, 2026, after a turbulent period marked by gene therapy safety concerns, regulatory conflict and a stock decline of nearly 90% from early 2025. The leadership change
AstraZeneca and Bristol Myers Squibb have reportedly discussed a potential combination that could value the new group at nearly $400 billion. The talks remain preliminary, and neither company has announced a transaction. However, its scale and overlapping oncology portfolios matter
Clinical trials now collect an average of 5.9 million data points in each Phase III protocol, while many sponsors still depend on manual, periodic reviews. This mismatch can delay the detection of protocol deviations, safety signals, and data inconsistencies. As
Hippocratic AI acquired Grove AI in January 2026 after the startup spent two years building voice agents for clinical trial recruitment. Grove’s technology speaks with patients, collects screening information and helps match them with enrolling studies. The deal shows how